Steps taken following prequalification of [HA743 trade name]*:

This document will only list changes endorsed by WHO Prequalification Team – Medicines that affect the WHOPAR.

No changes.

(Cipla Limited), HA743

Abacavir (sulfate)/lamivudine 600 mg/300 mg tablets

^{*} Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.